HT 002
Alternative Names: HT-002Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Virginia Commonwealth University
- Developer Hoth Therapeutics; Virginia Commonwealth University
- Class Antivirals; Peptides
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA
- 05 May 2021 Hoth Therapeutics expands its research agreement with Virginia Commonwealth University for HT 002 in SARS-CoV2 variants
- 23 Mar 2021 Pharmacodynamics data from a preclinical studies in COVID-2019 infections released by Hoth Therapeutics